Pyrido pyrimidinones as selective agonists of the high affinity niacin receptor GPR109A: Optimization of in vitro activity

被引：10
作者：
Peters, Jens-Uwe [1 ]
Kuehne, Holger [1 ]
Dehmlow, Henrietta [1 ]
Grether, Uwe [1 ]
Conte, Aurelia [1 ]
Hainzl, Dominik [1 ]
Hertel, Cornelia [1 ]
Kratochwil, Nicole A. [1 ]
Otteneder, Michael [1 ]
Narquizian, Robert [1 ]
Panousis, Constantinos G. [2 ]
Ricklin, Fabienne [1 ]
Roever, Stephan [1 ]
机构：
[1] F Hoffmann La Roche Ltd, Pharma Res, CH-4070 Basel, Switzerland
[2] F Hoffmann La Roche Ltd, Pharma Res, Nutley, NJ 07110 USA
来源：
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2010年 / 20卷 / 18期
关键词：
Flushing; GPR109A; GPR109B; GPCR; Lead identification; Lipolysis; Niacin; Pyrido pyrimidinone; NICOTINIC-ACID RECEPTOR; ESTER TRANSFER PROTEIN; MOLECULAR-IDENTIFICATION; RELEASE NIACIN; EFFICACY; CHOLESTEROL; MECHANISMS; EXPRESSION; DISCOVERY; SAFETY;
D O I：
10.1016/j.bmcl.2010.07.108
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
Pyrido pyrimidinones are selective agonists of the human high affinity niacin receptor GPR109A (HM74A). They show no activity on the highly homologous low affinity receptor GPR109B (HM74). Starting from a high throughput screening hit the in vitro activity of the pyrido pyrimidinones was significantly improved providing lead compounds suitable for further optimization. (c) 2010 Elsevier Ltd. All rights reserved.
引用
收藏
页码：5426 / 5430
页数：5
相关论文
共 30 条
  • [21] Potent tricyclic pyrazole tetrazole agonists of the nicotinic acid receptor (GPR109a)
    Boatman, P. Douglas
    Schrader, Thomas O.
    Kasem, Michelle
    Johnson, Benjamin R.
    Skinner, Philip J.
    Jung, Jae-Kyu
    Xu, Jerry
    Cherrier, Martin C.
    Webb, Peter J.
    Semple, Graeme
    Sage, Carleton R.
    Knudsen, Jens
    Chen, Ruoping
    Taggart, Andrew K.
    Carballo-Jane, Ester
    Richman, Jeremy G.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2010, 20 (09) : 2797 - 2800
  • [22] Niacin receptor GPR109A inhibits insulin secretion and is down-regulated in type 2 diabetic islet beta-cells
    Wang, Na
    Guo, De-yu
    Tian, Xiong
    Lin, Hao-peng
    Li, Yun-pan
    Chen, Shao-jun
    Fu, Yu-cai
    Xu, Wen-can
    Wei, Chi-ju
    GENERAL AND COMPARATIVE ENDOCRINOLOGY, 2016, 237 : 98 - 108
  • [23] Involvement of the Niacin Receptor GPR109a in the Local Control of Glucose Uptake in Small Intestine of Type 2 Diabetic Mice
    Wong, Tung Po
    Chan, Leo Ka Yu
    Leung, Po Sing
    NUTRIENTS, 2015, 7 (09) : 7543 - 7561
  • [24] Niacin mitigates blood-brain barrier tight junctional proteins dysregulation and cerebral inflammation in ketamine rat model of psychosis: Role of GPR109A receptor
    Ibrahim, Weam W.
    Sayed, Rabab H.
    Kandil, Esraa A.
    Wadie, Walaa
    PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2022, 119
  • [25] A Randomized, Placebo-Controlled Trial to Assess the Effects of 8 Weeks of Administration of GSK256073, a Selective GPR109A Agonist, on High-Density Lipoprotein Cholesterol in Subjects With Dyslipidemia
    Olson, Eric J.
    Mahar, Kelly M.
    Haws, Thomas F.
    Fossler, Michael J.
    Gao, Feng
    de Gouville, Anne-Charlotte
    Sprecher, Dennis L.
    Lepore, John J.
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2019, 8 (07): : 871 - 883
  • [26] Structure-activity relationships of trans-substituted-propenoic acid derivatives on the nicotinic acid receptor HCA2 (GPR109A)
    van Veldhoven, J. P. D.
    Blad, C. C.
    Artsen, C. M.
    Klopman, C.
    Wolfram, D. R.
    Abdelkadir, M. J.
    Lane, J. R.
    Brussee, J.
    IJzerman, A. P.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2011, 21 (09) : 2736 - 2739
  • [27] Hierarchical virtual screening: identification of potential high-affinity and selective β3-adrenergic receptor agonists
    Saxena, A. K.
    Roy, K. K.
    SAR AND QSAR IN ENVIRONMENTAL RESEARCH, 2012, 23 (5-6) : 389 - 407
  • [28] Selective CB2 receptor agonists. Part 2: Structure-activity relationship studies and optimization of proline-based compounds
    Riether, Doris
    Zindell, Renee
    Wu, Lifen
    Betageri, Raj
    Jenkins, James E.
    Khor, Someina
    Berry, Angela K.
    Hickey, Eugene R.
    Ermann, Monika
    Albrecht, Claudia
    Ceci, Angelo
    Gemkow, Mark J.
    Nagaraja, Nelamangala V.
    Romig, Helmut
    Sauer, Achim
    Thomson, David S.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2015, 25 (03) : 581 - 586
  • [29] Discovery of a Biaryl Cyclohexene Carboxylic Acid (MK-6892): A Potent and Selective High Affinity Niacin Receptor Full Agonist with Reduced Flushing Profiles in Animals as a Preclinical Candidate
    Shen, Hong C.
    Ding, Fa-Xiang
    Raghavan, Subharekha
    Deng, Qiaolin
    Luell, Silvi
    Forrest, Michael J.
    Carballo-Jane, Ester
    Wilsie, Larissa C.
    Krsmanovic, Mihajlo L.
    Taggart, Andrew K.
    Wu, Kenneth K.
    Wu, Tsuei-Ju
    Cheng, Kang
    Ren, Ning
    Cai, Tian-Quan
    Chen, Qing
    Wang, Junying
    Wolff, Michael S.
    Tong, Xinchun
    Holt, Tom G.
    Waters, M. Gerard
    Hammond, Milton L.
    Tata, James R.
    Colletti, Steven L.
    JOURNAL OF MEDICINAL CHEMISTRY, 2010, 53 (06) : 2666 - 2670
  • [30] 4-(3-Aminoazetidin-1-yl)pyrimidin-2-amines as High-Affinity Non-imidazole Histamine H3 Receptor Agonists with in Vivo Central Nervous System Activity
    Wagner, Gabor
    Mocking, Tamara A. M.
    Arimont, Marta
    Provensi, Gustavo
    Rani, Barbara
    Silva-Marques, Bruna
    Latacz, Gniewomir
    Pereira, Daniel Da Costa
    Karatzidou, Christina
    Vischer, Henry F.
    Wijtmans, Maikel
    Kiec-Kononowicz, Katarzyna
    de Esch, Iwan J. P.
    Leurs, Rob
    JOURNAL OF MEDICINAL CHEMISTRY, 2019, 62 (23) : 10848 - 10866
123